Wave Life Sciences Ltd. (WVE) Stock
WVE has an Alpha Score of 14 out of 100 (poor), computed on Nov 8, 2026 from 2 of 4 sub-scores.
What is WVE's Alpha Score?
How it works →Alpha Score of 14 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Are Wave Life Sciences Ltd. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 12, 26 | Rawcliffe Adrian | Director | SELL | 12.7K | $67K |
| Aug 11, 26 | Tan Aik Na | Director | SELL | 432 | $3K |
| Aug 11, 26 | Takanashi Ken | Director | SELL | 3.9K | $23K |
| Aug 11, 26 | Wagner Heidi L | Director | SELL | 7.0K | $42K |
| Dec 11, 25 | Gsk Plc | 10%+ Owner | BUY | 1.47M | $27.9M |
| Sep 27, 24 | Gsk Plc | 10%+ Owner | BUY | 2.79M | $22.3M |
| Dec 7, 23 | Gsk Plc | 10%+ Owner | BUY | 3.30M | $16.5M |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are WVE's key statistics?
Key statistics as of Oct 31, 2026
How does WVE's valuation compare with the Healthcare sector?
| Metric | WVE | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -309.73% | 3.60% | 175 |
| Return on equity | -49.87% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
WVE price chart
Powered by TradingViewWhat does Wave Life Sciences Ltd. do?
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health. It leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities such as RNA editing, splicing, antisense silencing, and RNA interference, along with chemistry innovation and insights from human genetics. This enables the development of first- or best-in-class therapeutics for both rare and prevalent disorders. The company's pipeline features clinical programs addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as preclinical efforts in obesity. These initiatives target diseases originating in the liver, muscle, central nervous system, and other tissues, aiming to deliver disease-modifying therapies with life-changing potential. Founded in 2012 and headquartered in Cambridge, Massachusetts, with operations in Singapore, Wave Life Sciences Ltd. plays a key role in advancing precision medicine for genetic conditions through innovative RNA-based approaches.